1. Home
  2. LBRX vs IQ Comparison

LBRX vs IQ Comparison

Compare LBRX & IQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LB Pharmaceuticals Inc

LBRX

LB Pharmaceuticals Inc

HOLD

Current Price

$31.92

Market Cap

889.0M

Sector

Health Care

ML Signal

HOLD

Logo iQIYI Inc.

IQ

iQIYI Inc.

HOLD

Current Price

$0.99

Market Cap

1.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
LBRX
IQ
Founded
2015
2009
Country
United States
China
Employees
27
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Consumer Electronics/Video Chains
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
889.0M
1.0B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
LBRX
IQ
Price
$31.92
$0.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$46.60
$2.91
AVG Volume (30 Days)
227.2K
5.7M
Earning Date
05-06-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$0.28
Revenue Next Year
N/A
$3.54
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.40
$0.95
52 Week High
$33.47
$2.76

Technical Indicators

Market Signals
Indicator
LBRX
IQ
Relative Strength Index (RSI) 63.93 34.52
Support Level $26.75 $0.98
Resistance Level $33.47 $1.19
Average True Range (ATR) 1.73 0.04
MACD 0.33 0.00
Stochastic Oscillator 86.22 30.95

Price Performance

Historical Comparison
LBRX
IQ

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

About IQ iQIYI Inc.

Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.

Share on Social Networks: